Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia
The Lancet Haematology in conversation with
English - November 25, 2021 11:00 - 11 minutes - 8.27 MBLife Sciences Science Education blood haemophilia haematology leukaemia Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Raul Cordoba on haematological malignancies in older people
Next Episode: Fredrik Schjesvold on OCEAN phase 3
Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv